Abstract
Chronic heart failure (CHF) is the performance of end-stage cardiovascular disease and the leading cause of death in recent years.With the rapid development of medical care, the mortality rate of heart failure is still high.This is one in the two major challenges in the cardiovascular field in the 21st century.The new drug LCZ696 is a dual inhibitors of angiotensin receptor blockers (ARB) and neprilysin (NEP), which may lead to new hope for patients with heart failure.In order to determine the efficacy and safety of LCZ696 in the treatment of heart failure, foreign countries have carried out some large-scale trials, such as PARAMOUT, PARADIGM, TITRATION and so on.The results of these studies reflected the superiority of LCZ696 compared with enalapril, valsartan and other drugs in the treatment of chronic heart failure.ARB/antiotensin converting enzyme inhibitors(ACEI) targets the angiotensin receptor to dilate blood vessels and inhibits the sympathetic nerve, but their effects on sodium withdrawal and diuresis are weak.The sacubitril in LCZ696 prevents natriuretic peptide from degrading, strengthens the natriuretic diuretic and further expansion of blood vessels.Thereby it improves water and sodium retention and cardiac function.It can play a better synergistic role combined with valsartan. Key words: LCZ696; Angiotensin receptor blockers; Neprilysin; Heart failure
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
